Achieving diversity and inclusion in clinical trials is both a moral imperative and a scientific and regulatory necessity. Diverse participant populations ensure that study findings are applicable to a broader range of patients, leading to more effective and equitable healthcare solutions. Despite efforts to improve diversity, many trials still struggle to recruit representative patient cohorts. Improving diversity in clinical trials requires a multifaceted approach. By harnessing the power of artificial intelligence (AI) augmented by human expertise, we can unlock new opportunities to enhance patient diversity in clinical trials through data-driven site selection.
The regulatory and scientific necessity for diversity
Regulatory bodies have increasingly emphasised the importance of diversity in clinical trials. For example, the FDA's guidance on diversity in clinical trial populations highlights the need for including underrepresented demographic groups to ensure the safety and efficacy of medical products. The FDA also requires diversity action plans to ensure concrete steps are taken to improve diversity in a trial and that it is strategically incorporated into planning as early as possible.
Diverse clinical trials are scientifically crucial for several reasons:
- Generalisability of results: When trials include diverse populations, the findings are more likely to be applicable to a wide range of patients. This helps in developing treatments that are effective across different demographic groups, reducing health disparities.
- Understanding differential responses: Different populations can respond differently to treatments due to genetic, environmental, and lifestyle factors including social determinants of health. Including diverse participants in trials helps identify these variations and tailor therapies accordingly.
- Safety and efficacy: Ensuring a treatment’s safety and efficacy across all target populations requires testing in those segments. Without diverse participation, some groups may face higher risks or reduced efficacy from treatments developed based on homogenous data.
Demonstrating robust safety and efficacy data across appropriately representative populations is key for registrational studies, regulatory approval and commercialisation. Selecting sites that improve access to target communities can significantly benefit a trial by getting the right data the first time, avoiding costly delays or additional trials.
Integrating diversity data in decision-making
Accurately measuring diversity data requires more nuance than assigning an overall diversity score. It involves understanding the diversity within the disease population and the therapy’s target population. Leveraging data like prevalence to participation ratios (PPR) and participation consumption ratios (PCR) helps identify the appropriate target populations, overlooked or underrepresented groups, and groups with highest unmet need.
Human-enabled AI can analyse vast datasets with precision and efficiency. One Search, for example, can integrate multiple datasets like our Symphony Health Integrated Dataverse®, claims data, census data, and other third-party data to provide researchers with clear insights into enhancing diversity. Understanding which patient populations have the highest need, where they are located, and their unique patient journeys will help optimise site selection decision-making along with other operational and feasibility criteria.
Identifying diverse connections in site selection
Specialised AI like ICON’s One Search allows us to assess the connectedness of sites, institutions and investigators and their access to patients. Implementing human-enabled AI to map these connections, has shown that increased connectedness correlates to higher enrolment performance. AI can rank the quality of these connections by overlaying additional layers of data, including evaluations of site performance and core clinical fit, ensuring a more comprehensive and effective recruitment strategy.
Using One Search, we can select sites connected to underrepresented communities to improve clinical trial access within key geographies and communities. Access to clinical trials is a major hurdle to participation for diverse patient populations, and using a novel lens to identify sites opens possibilities to build trusting relationships with communities, clinicians and patients that have historically not been included.1
The role of investigators
Gathering additional population data and demographic breakdowns of the institutions’ patient populations and examining what patients the principal investigators are treating is crucial.
Diversity is also a challenge within healthcare professions. Clinicians who share a cultural alignment with the target populations are more likely to successfully enrol those patients into trialsi due in part to the inherent cultural competency of shared culture or community, enhanced trust building, and a deeper understanding of patient motivations and barriers for participation. For example, there was a reported 50% increase in the proportion of female participants in heart failure trials when the investigators were female.2
Choosing connected investigators can boost enrolment and support expedient recruitment solutions. On the other hand, ineffective investigators can cause costly delays or failure to meet recruitment goals, jeopardising the feasibility of a trial. Fortunately, the right AI can leverage demographics data, past performance, and patient data to evaluate and predict investigator effectiveness in recruitment. The result is a refined, country-specific list of investigators that feasibility analysts can incorporate into site assessments. This data-driven personnel analysis contributes to accelerated site identification timelines, enhances investigator engagement, and increases the likelihood of reaching overall diversity and patient recruitment goals.
Conclusion
Diversity in clinical trials is essential for ensuring that clinical research and the resulting treatments are effective for broader populations. By combining AI with human expertise, tools like One Search offer a promising path forward and enable sponsors to better address the complex factors that influence patient participation in a study.
This human-enabled AI process integrates the identification and recruitment of diverse participant populations into site selection, ensuring that clinical trials are both inclusive and effective to meet scientific rigor and regulatory requirements. Embracing these innovative strategies will not only enhance the quality of clinical research but also contribute to a more equitable healthcare system and meaningful therapies for patients in need.
To learn more about unlocking the benefits of AI-enabled site selection, read our whitepaper or connect with us today.
References
1 Zhu, J, D'Angelo, F, Miranda, J. et al. Incorporating Cultural Competence and Cultural Humility in Cardiovascular Clinical Trials to Increase Diversity Among Participants. J Am Coll Cardiol. 2022 Jul, 80 (1) 89–92. https://doi.org/10.1016/j.jacc.2022.05.001
2 Reza N, Tahhan AS, Mahmud N, DeFilippis EM, Alrohaibani A, Vaduganathan M, Greene SJ, Ho AH, Fonarow GC, Butler J, O’Connor C, Fiuzat M, Vardeny O, Piña IL, Lindenfeld J, Jessup M. Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. Circ Heart Fail. 13 (2020) e006605.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel